Mandate

Vinge has advised CELLINK in a directed issue of new shares

Vinge has advised CELLINK AB (publ) in connection with a directed issue of new shares which will generate approximately MSEK 377 for CELLINK.

The subscription price was determined through an accelerated book‑building and corresponds to a discount of 3.4 per cent compared with the volume‑weighted average listed price during January on Nasdaq First North Growth Market. In addition to considerable support from existing shareholders, several new Swedish and institutional shareholders subscribed for the new issue of shares. An amount of MSEK 150 from the proceeds in relation to the new issue of shares will be used to finance the company’s organic growth plan, future operating capital requirements, etc. and the remaining proceeds can be used to finance strategic acquisitions.

Vinge’s team consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023

Vinge has advised private equity firm Stirling Square Capital Partners

Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023